Published • loading... • Updated
Ozempic Maker Novo Nordisk’s Investors Are Nervously Looking Into the Future
More than 1.5 million people have started the pill since January, but investors worry about patent expiry, competition and a sales mix heavily tied to obesity drugs.
Summary by BizToc
7 Articles
7 Articles
Sydney Morning Herald+3 Reposted by 3 other sources
Ozempic’s maker is in trouble. Tablets may be the answer
Just a few years ago, Novo Nordisk was the darling of the healthcare industry. Now it is teetering.
·North Sydney, Australia
Read Full Article
They are among the most expensive for both the state and the individual citizens: because they are very popular and the patent will expire only in 5 years
·Italy
Read Full Article
New Nordisk CEO Mike Doustdar has been ahead of a restructuring of the company for a year. According to him, investors still underestimate the potential of the company's drugs The post The creator of Ozempic needs a new chapter. The pills can be the answer appeared first on InfoMoney.
Coverage Details
Total News Sources7
Leaning Left4Leaning Right0Center1Last UpdatedBias Distribution80% Left
Bias Distribution
- 80% of the sources lean Left
80% Left
L 80%
C 20%
Factuality
To view factuality data please Upgrade to Premium
